
RUBY
NCT02505048
A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
Status:
Recruiting

II
Phase

Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
BRCA1/2
Investigational
Product
Rucaparib
Treatment Arms
o Experimental: rucaparib